Drug recall · January 3, 2024
ANORO ELLIPTA recall
Why: Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10
- Lots / codes
Lot #: 7Y9S. Exp June 2025
- Quantity
- 67,508 inhalers
- Company
- GlaxoSmithKline LLC, Durham, NC
- Distribution
- Distributed Nationwide in the USA and Puerto Rico.
- Initiated
- December 12, 2023 · Voluntary: Firm initiated
- Classified
- December 22, 2023
- Reported
- January 3, 2024
- Ended
- September 12, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Anoro
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.